Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease

Table 3

Pharmacotherapies for osteoporosis according to stage of chronic kidney disease (CKD).

Agents	CKD stage ≤ 3 without biochemical abnormalities	CKD stage > 3 with biochemical abnormalities	Dialysis (stage 5D)
Alendronate	+	−	+
Risedronate	+	−	−
Etidronate	−	−	−
Ibandronate	+	+	+
Minodronate	+	+	+
Denosumab	+	+	+
Raloxifene	+	+	+
Teriparatide	+	+	+

+: use with caution; −: avoid use.